Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01828008
Recruitment Status : Unknown
Verified January 2013 by Han weidong, Chinese PLA General Hospital. Recruitment status was: Not yet recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
the patients with CD20-positive Lymphomas
- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy
- to refuse the therapy and need not tolerate the therapy